ArticleActa neuropathologica communications2025
Amyloid quantification in the oldest-old: selecting regions for optimizing correspondence between postmortem pathology and amyloid PET.
Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebellar cortical amyloid deposition biasesEuropean journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Positron emission tomography (PET) is the current gold standard for assessing amyloid burden in vivo and is often quantified using standardized uptake value ratios (SUVRs). We evaluated the performance of four SUVR calculation methods for predicting amyloid deposition at autopsy in a group of oldest-old participants. We analyzed data from 165 participants from The 90 + Study with both florbetapir PET and postmortem assessments. PET scans were re-aligned to an older age template using a custom MRI-free pipeline. SUVRs were computed from two target regions—combined posterior cingulate and precuneus (PC2) and an established cortical summary region—and two reference regions—white matter (WM) and cerebellar gray matter. Their predictive performance for amyloid beta positivity (Thal phase ≥ 3) and neuritic plaque positivity (moderate or frequent CERAD score) was evaluated using receiver operating characteristic analyses, including DeLong’s test for comparisons. Participants had a mean (± standard deviation) age at PET of 94 ± 3 years, and age at death of 97 ± 4 years. Most participants had amyloid at autopsy: 113 (68%) were amyloid beta positive, and 104 (63%) were neuritic plaque positive. The best performing SUVR was the PC2+WM, yielding an area under the curve (AUC) of 0.84 (95% CI 0.78–0.90) for amyloid beta and 0.82 (95% CI 0.76–0.89) for neuritic plaque, with an optimal cutoff of 0.77 for both outcomes. Reference and target region selection was more consequential for predicting amyloid beta positivity, with the WM consistently outperforming the cerebellar gray matter as a reference region for both target regions, while the PC2 significantly outperformed the cortical summary region for the cerebellar gray matter reference (P < 0.001) but only trended for significance for the WM reference (P = 0.069, DeLong’s test). Our findings suggest that using a WM reference and a limited cortical target region may improve PET-neuropathology correspondence, especially in older cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.